Hidroxicarbamida Medac (Hydroxycarbamide)

Hidroxicarbamida Medac is indicated for several hematologic and oncologic conditions where reduction of abnormal cell proliferation is desired.

• Chronic myelogenous leukemia (CML)
• Polycythemia vera
• Essential thrombocythemia
• Sickle cell disease (to reduce vaso‑occlusive crises)
• Melanoma (as adjunct therapy)
• Use in combination with other chemotherapeutic agents as directed by an oncologist

• Hydroxycarbamide inhibits the enzyme ribonucleotide reductase, which is essential for converting ribonucleotides to deoxyribonucleotides. By limiting the pool of deoxyribonucleotides, the drug impairs DNA synthesis and repair, preferentially affecting rapidly dividing cells such as malignant leukemic cells and hyperproliferative hematopoietic clones. This reduction in DNA replication leads to cell cycle arrest, particularly in the S phase, and promotes apoptosis of abnormal cells.

Adverse reactions to Hidroxicarbamida Medac vary in frequency and severity.

Common

• Nausea and vomiting
• Loss of appetite
• Mild skin rash
• Mild leukopenia or anemia

Serious

• Severe bone marrow suppression (pancytopenia)
• Hepatic toxicity
• Renal impairment
• Severe cutaneous reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before initiating therapy with Hidroxicarbamida Medac, clinicians should evaluate several safety considerations.

• Obtain baseline complete blood count, liver and kidney function tests.
• Assess pregnancy status; avoid use during pregnancy unless benefits outweigh risks.
• Do not use in patients with pre‑existing severe bone marrow failure.
• Monitor for signs of infection or fever during treatment.
• Adjust dose in patients with renal impairment.
• Advise patients to avoid live attenuated vaccines while on therapy.

Hydroxycarbamide can interact with other medicines, affecting its efficacy or safety.

Avoid

• Concurrent use with protease inhibitors (e.g., ritonavir) that increase hydroxycarbamide levels.
• Co‑administration with high‑dose vitamin C, which may enhance toxicity.
• Combination with other myelosuppressive agents without dose adjustment.

Use with caution

• Allopurinol may increase risk of bone marrow suppression.
• NSAIDs may increase risk of renal dysfunction.
• Azathioprine may require close monitoring of blood counts.